<status value="draft"/><publisher value="HL7 International / Clinical Decision Support"/><contact><telecom><system value="url"/><value value="http://www.hl7.org/Special/committees/dss"/></telecom></contact><relatesTo><type><coding><system value="http://terminology.hl7.org/CodeSystem/artifact-relationship-type"/><code value="cites"/><display value="Cites"/></coding></type><targetMarkdown value="Analysis 1.16 from Wardlaw 2014 Citation: Wardlaw JM, Murray V, Berge E, del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2014 Jul 29(7):CD000213. PMID 25072528 URL: https://doi.org/10.1002/14651858.CD000213.pub3"/></relatesTo><description value="mRS 3-6 at 90 days Odds Ratio 0.65 for Alteplase vs. No Alteplase in patients with acute ischemic stroke 0-3 hours prior"/><variableDefinition><variableRole value="population"/><observed><reference value="EvidenceVariable/Wardlaw2014Analysis1.16.3EvidenceSet"/><type value="EvidenceVariable"/><display value="Wardlaw 2014 Analysis 1.16.3 Evidence set"/></observed><intended><reference value="Group/AcuteIschemicStroke0-3Hours"/><type value="Group"/><display value="stroke at 0-3 hours"/></intended></variableDefinition><variableDefinition><variableRole value="outcome"/><observed><reference value="EvidenceVariable/example-mRS3-6-at-90days"/><type value="EvidenceVariable"/><display value="mRS 3-6 at 90 days"/></observed><intended><reference value="EvidenceVariable/example-dead-or-dependent-90day"/><type value="EvidenceVariable"/><display value="Dead or functionally dependent at 90 days"/></intended></variableDefinition><variableDefinition><variableRole value="exposure"/><comparatorCategory value="No Alteplase"/><observed><reference value="EvidenceVariable/example-group-assignment-alteplase-for-stroke-vs-no-alteplase"/><type value="EvidenceVariable"/><display value="Group Assignment: Alteplase for Stroke vs No Alteplase"/></observed></variableDefinition><synthesisType><coding><system value="http://terminology.hl7.org/CodeSystem/synthesis-type"/><code value="std-MA"/><display value="summary data meta-analysis"/></coding></synthesisType><studyDesign><coding><system value="https://fevir.net/sevco"/><code value="SEVCO:01003"/><display value="randomized assignment"/></coding></studyDesign><statistic><statisticType><coding><system value="https://fevir.net/sevco"/><code value="STATO:0000182"/><display value="odds ratio"/></coding></statisticType><quantity><value value="0.65"/></quantity><numberOfEvents value="1137"/><sampleSize><numberOfStudies value="6"/><numberOfParticipants value="1779"/></sampleSize><attributeEstimate><description value="95% CI 0.54 to 0.80"/><type><coding><system value="http://terminology.hl7.org/CodeSystem/attribute-estimate-type"/><code value="C53324"/><display value="Confidence interval"/></coding></type><level value="0.95"/><range><low><value value="0.54"/></low><high><value value="0.8"/></high></range></attributeEstimate><attributeEstimate><description value="P-value = 0.000023"/><type><coding><system value="http://terminology.hl7.org/CodeSystem/attribute-estimate-type"/><code value="C44185"/><display value="P-value"/></coding></type><quantity><value value="0.000023"/></quantity></attributeEstimate><attributeEstimate><description value="Heterogeneity I-sq = 0.0%"/><type><coding><system value="http://terminology.hl7.org/CodeSystem/attribute-estimate-type"/><code value="0000420"/><display value="I-squared"/></coding></type><quantity><value value="0"/><unit value="%"/><system value="http://unitsofmeasure.org"/><code value="%"/></quantity></attributeEstimate></statistic><certainty><description value="Moderate certainty due to risk of bias"/><type><coding><system value="http://terminology.hl7.org/CodeSystem/certainty-type"/><code value="Overall"/><display value="Overall certainty"/></coding></type><rating><coding><system value="http://terminology.hl7.org/CodeSystem/certainty-rating"/><code value="moderate"/><display value="Moderate quality"/></coding></rating><subcomponent><type><coding><system value="http://terminology.hl7.org/CodeSystem/certainty-type"/><code value="PublicationBias"/><display value="Publication bias"/></coding></type><rating><coding><system value="http://terminology.hl7.org/CodeSystem/certainty-rating"/><code value="no-concern"/><display value="no serious concern"/></coding></rating></subcomponent><subcomponent><type><coding><system value="http://terminology.hl7.org/CodeSystem/certainty-type"/><code value="Inconsistency"/><display value="Inconsistency"/></coding></type><rating><coding><system value="http://terminology.hl7.org/CodeSystem/certainty-rating"/><code value="no-concern"/><display value="no serious concern"/></coding></rating></subcomponent><subcomponent><type><coding><system value="http://terminology.hl7.org/CodeSystem/certainty-type"/><code value="Imprecision"/><display value="Imprecision"/></coding></type><rating><coding><system value="http://terminology.hl7.org/CodeSystem/certainty-rating"/><code value="no-concern"/><display value="no serious concern"/></coding></rating></subcomponent><subcomponent><type><coding><system value="http://terminology.hl7.org/CodeSystem/certainty-type"/><code value="Indirectness"/><display value="Indirectness"/></coding></type><rating><coding><system value="http://terminology.hl7.org/CodeSystem/certainty-rating"/><code value="no-concern"/><display value="no serious concern"/></coding></rating></subcomponent><subcomponent><note><text value="results largely influenced by IST-3 trial which was unblinded and NINDS trial which had allocation concealment not stated and baseline imbalances"/></note><type><coding><system value="http://terminology.hl7.org/CodeSystem/certainty-type"/><code value="RiskOfBias"/><display value="Risk of bias"/></coding></type><rating><coding><system value="http://terminology.hl7.org/CodeSystem/certainty-rating"/><code value="serious-concern"/><display value="serious concern"/></coding></rating></subcomponent></certainty></Evidence>

"Effect of Alteplase vs No alteplase on mRS 3-6 at 90 days in Stroke 0-3 hours prior" is a comparative effect estimate.